These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8097126)

  • 1. Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties.
    Möller HJ
    Eur Neuropsychopharmacol; 1993 Mar; 3(1):1-11. PubMed ID: 8097126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Incidence of the deficit form in refractory schizophrenia].
    Samuelian JC
    Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].
    Möller HJ
    Nervenarzt; 2000 May; 71(5):345-53. PubMed ID: 10846709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical neuroleptics: a new approach in the treatment of negative symptoms.
    Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 4():99-107. PubMed ID: 10654115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation trial on the efficacy of neuroleptics on the outcome of schizophrenia].
    Dollfus S; Petit M
    Encephale; 1991; 17(4):247-53. PubMed ID: 1683625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clozapine and treatment of negative symptoms].
    Lançon C; Farisse J; Llorca PM
    Encephale; 1997 Sep; 23 Spec No 4():7-11. PubMed ID: 9417403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative and deficit symptoms in schizophrenia do respond to neuroleptics.
    Goldberg SC
    Schizophr Bull; 1985; 11(3):453-6. PubMed ID: 2863872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone: how good is the evidence for efficacy?
    Mattes JA
    Schizophr Bull; 1997; 23(1):155-61. PubMed ID: 9050121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients].
    Briken P; Nika E; Krausz M; Naber D
    Fortschr Neurol Psychiatr; 2002 Mar; 70(3):139-44. PubMed ID: 11880946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment.
    Peralta V; Cuesta MJ; Martinez-Larrea A; Serrano JF
    Am J Psychiatry; 2000 Sep; 157(9):1461-6. PubMed ID: 10964863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic-resistant schizophrenics.
    Murray JB
    J Psychol; 1989 Jan; 123(1):69-78. PubMed ID: 2564435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tolerance of neuroleptics, deficit syndrome and cognitive functions].
    Kahn JP
    Encephale; 1996 Jun; 22 Spec No 2():49-54. PubMed ID: 8767043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic nonresponse and affective symptoms: a 2-year prospective study of schizophrenic outpatients.
    Faraone SV; Young AS; Brown WA
    Psychiatry Res; 1989 Jun; 28(3):315-21. PubMed ID: 2569751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Profile of the action of neuroleptics in deficit schizophrenia].
    Vanelle JM
    Encephale; 1996 Jun; 22 Spec No 2():33-9. PubMed ID: 8767040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacologic and cognitive therapy treatment strategies in in persistent negative schizophrenic symptoms].
    Vauth R; Dreher-Rudolph M; Stieglitz RD
    Fortschr Neurol Psychiatr; 1999 Jun; 67(6):261-73. PubMed ID: 10399046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroleptic treatment of late-life schizophrenia.
    Salzman C; Tune L
    Harv Rev Psychiatry; 2001; 9(2):77-83. PubMed ID: 11266405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Deficit: the value and difficulty of defining the primary or secondary character of observed symptoms].
    Petit M; Langlois S
    Encephale; 1996 Jun; 22 Spec No 2():13-8. PubMed ID: 8767036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
    Meltzer HY; Sommers AA; Luchins DJ
    J Clin Psychopharmacol; 1986 Dec; 6(6):329-38. PubMed ID: 2879856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to neuroleptic drugs as a device for classifying schizophrenia.
    Brown WA; Herz LR
    Schizophr Bull; 1989; 15(1):123-9. PubMed ID: 2566199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.